Altimmune, Inc.ALTNASDAQ

Revenue (LTM)

$41000

+105.0% YoY

Net Income (LTM)

$-88M

+7.3% YoY

Free Cash Flow

$-68M

Revenue CAGR (5Y)

-68.9%

Marginsdeclining

FCF($0.1B)

Unprofitable

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Revenue	4	-0↓101.5%	0↑726.5%	0↓95.3%	0↑105.0%
Gross Profit	4	-0↓101.5%	0↑726.5%	0↓95.3%	-0↓455.0%
Operating Income	-97	-88↑9.5%	-96↓9.3%	-103↓7.6%	-94↑8.4%
Net Income	-97	-85↑12.7%	-88↓4.4%	-95↓7.5%	-88↑7.3%
EBITDA	-97	-84↑12.6%	-88↓4.2%	-95↓7.8%	-94↑0.3%
EPS Diluted	-2.35	-1.81↑23.0%	-1.66↑8.3%	-1.34↑19.3%	-1.00↑25.4%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Cash & Equivalents	190	111↓41.6%	135↑21.6%	37↓72.7%	44↑18.5%
Total Current Assets	204	193↓5.5%	210↑8.7%	137↓34.5%	278↑102.7%
Total Assets	219	207↓5.5%	211↑1.8%	139↓33.9%	280↑100.9%
Total Current Liabilities	18	17↓6.7%	12↓28.8%	10↓13.8%	15↑43.3%
Total Liabilities	20	22↑9.7%	17↓23.5%	16↓4.5%	55↑248.4%
Total Equity	199	185↓7.0%	194↑4.8%	124↓36.4%	225↑82.1%
Total Debt	2	1↓26.8%	1↓40.3%	2↑150.5%	36↑2023.0%
Net Debt	-189	-110↑41.7%	-134↓22.3%	-35↑73.8%	-8↑77.1%

Metric	Dec 21	Dec 22	Dec 23	Dec 24	Dec 25
Operating Cash Flow	-78	-63↑20.0%	-76↓21.1%	-80↓5.3%	-68↑15.4%
Capital Expenditure	-12	-0↑99.0%	-0↑62.7%	0	-0
Free Cash Flow	-91	-63↑30.7%	-76↓21.0%	-80↓5.3%	-68↑15.4%
Stock-Based Comp	6	8↑46.8%	11↑31.3%	14↑35.3%	16↑11.7%
Net Change in Cash	74	-79↓206.5%	24↑130.3%	-98↓508.7%	7↑107.0%

Values in millions except EPS · Ratios shown as percentages · Click any metric to drill down

Explore More

Filter and sort all 500 stocks

Today's biggest gainers and losers

Visual sector performance